$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000162828024032321 Filed on July 19, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$14.06M	$14.00M	$50.16M
YoY Change	11.94%	7.12%	-6.9%
Cost Of Revenue	$7.072M	$7.250M	$29.40M
YoY Change	-7.96%	-1.2%	-0.44%
Gross Profit	$6.989M	$6.752M	$20.75M
YoY Change	43.31%	17.77%	-14.73%
Gross Profit Margin	49.7%	48.22%	41.38%
Selling, General & Admin	$4.206M	$4.538M	$18.13M
YoY Change	-9.28%	-1.24%	5.16%
% of Gross Profit	60.18%	67.21%	87.36%
Research & Development	$1.454M	$2.050M	$9.544M
YoY Change	-47.94%	-28.12%	-17.33%
% of Gross Profit	20.8%	30.36%	45.99%
Depreciation & Amortization	$449.0K	$457.0K	$1.700M
YoY Change	0.9%	-21.61%	-24.31%
% of Gross Profit	6.42%	6.77%	8.19%
Operating Expenses	$5.660M	$6.588M	$27.68M
YoY Change	-23.81%	-11.53%	-3.86%
Operating Profit	$1.329M	$164.0K	-$7.356M
YoY Change	-152.08%	-109.57%	65.34%
Interest Expense			$48.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$5.000K	$81.00K	$48.00K
YoY Change	-64.29%	-505.0%	-536.36%
Pretax Income	$1.334M	-$190.0K	-$7.308M
YoY Change	-152.56%	-92.52%	38.75%
Income Tax	$21.00K	-$81.00K	-$32.00K
% Of Pretax Income	1.57%
Net Earnings	$1.313M	-$109.0K	-$7.276M
YoY Change	-150.5%	-95.74%	36.38%
Net Earnings / Revenue	9.34%	-0.78%	-14.51%
Basic Earnings Per Share	$0.10		-$0.54
Diluted Earnings Per Share	$0.09	-$0.01	-$0.54
COMMON SHARES
Basic Shares Outstanding	13.59M shares		13.55M shares
Diluted Shares Outstanding	14.04M shares		13.55M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.892M	$2.618M	$2.618M
YoY Change	-40.6%	-74.13%	-74.13%
Cash & Equivalents	$2.892M	$2.618M	$2.618M
Short-Term Investments
Other Short-Term Assets	$1.254M	$1.495M	$1.495M
YoY Change	13.48%	12.58%	12.58%
Inventory
Prepaid Expenses
Receivables	$9.032M	$9.526M	$9.526M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.18M	$13.64M	$13.64M
YoY Change	-11.69%	-29.9%	-29.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.24M	$11.97M	$11.97M
YoY Change	-22.33%	-17.45%	-17.45%
Goodwill	$335.0K	$335.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$185.0K	$185.0K	$185.0K
YoY Change	0.54%	1133.33%	1133.33%
Total Long-Term Assets	$11.76M	$12.49M	$12.49M
YoY Change	-21.55%	-15.89%	-15.89%
TOTAL ASSETS
Total Short-Term Assets	$13.18M	$13.64M	$13.64M
Total Long-Term Assets	$11.76M	$12.49M	$12.49M
Total Assets	$24.93M	$26.13M	$26.13M
YoY Change	-16.63%	-23.84%	-23.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.235M	$5.800M	$5.800M
YoY Change	-9.1%	8.74%	8.74%
Accrued Expenses	$2.097M	$2.160M	$3.497M
YoY Change	0.29%	-37.9%	0.55%
Deferred Revenue	$10.31M	$12.09M
YoY Change	-7.45%	-5.34%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$151.0K
YoY Change
Total Short-Term Liabilities	$19.16M	$21.54M	$21.54M
YoY Change	-5.98%	-0.88%	-0.88%
LONG-TERM LIABILITIES
Long-Term Debt	$182.0K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$363.0K	$401.0K	$6.494M
YoY Change	-29.38%	-94.95%	-18.23%
Total Long-Term Liabilities	$363.0K	$401.0K	$6.494M
YoY Change	-29.38%	-94.95%	-18.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.16M	$21.54M	$21.54M
Total Long-Term Liabilities	$363.0K	$401.0K	$6.494M
Total Liabilities	$25.27M	$28.04M	$28.04M
YoY Change	-9.78%	-5.53%	-5.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$83.30M	-$84.60M
YoY Change	4.26%	9.44%
Common Stock	$83.66M	$83.40M
YoY Change	1.45%	1.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$332.0K	-$1.903M	-$1.903M
YoY Change
Total Liabilities & Shareholders Equity	$24.93M	$26.13M	$26.13M
YoY Change	-16.63%	-23.84%	-23.84%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	$1.313M	-$109.0K	-$7.276M
YoY Change	-150.5%	-95.74%	36.38%
Depreciation, Depletion And Amortization	$449.0K	$457.0K	$1.700M
YoY Change	0.9%	-21.61%	-24.31%
Cash From Operating Activities	$311.0K	-$1.816M	-$6.100M
YoY Change	-107.78%	162.43%	-253.58%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$111.0K	$836.0K
YoY Change	-100.0%	-114.61%	-70.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$111.0K	-$836.0K
YoY Change	-100.0%	-114.61%	-70.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$634.0K
YoY Change			5663.64%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$37.00K	-145.0K	-$527.0K
YoY Change	-93.73%	93.33%	-4890.91%
NET CHANGE
Cash From Operating Activities	$311.0K	-1.816M	-$6.100M
Cash From Investing Activities	$0.00	111.0K	-$836.0K
Cash From Financing Activities	-$37.00K	-145.0K	-$527.0K
Net Change In Cash	$274.0K	-1.850M	-$7.500M
YoY Change	-105.22%	21.15%	-775.07%
FREE CASH FLOW
Cash From Operating Activities	$311.0K	-$1.816M	-$6.100M
Capital Expenditures	$0.00	-$111.0K	$836.0K
Free Cash Flow	$311.0K	-$1.705M	-$6.936M
YoY Change	-106.66%	17.42%	-730.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-11504
CY2024	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-1401755
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	One University Plaza
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 307
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07601
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Hackensack
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024	dei	City Area Code CityAreaCode	201
CY2024	dei	Local Phone Number LocalPhoneNumber	808-8400
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7276000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7308000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5267000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-32000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	usd
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2023	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2023	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2024	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2024Q2	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-04-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	22000000	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13593766	shares
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	dei	Auditor Firm AuditorFirmId	274
CY2024	dei	Auditor Name AuditorName	EISNERAMPER LLP
CY2024	dei	Auditor Location AuditorLocation	West Palm Beach, Florida
CY2024Q2	us-gaap	Cash Cash	2618000	usd
CY2023Q2	us-gaap	Cash Cash	10118000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9526000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8011000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1495000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1328000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	13639000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	19457000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6252000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7318000	usd
CY2024Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	5721000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7186000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	185000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	335000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	335000	usd
CY2024Q2	us-gaap	Assets Assets	26132000	usd
CY2023Q2	us-gaap	Assets Assets	34311000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5800000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5334000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2160000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2270000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1337000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1208000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	150000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	145000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12094000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12776000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21541000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21733000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6093000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7391000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	401000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	551000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	28035000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	29675000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13714099	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13558650	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13593766	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13544228	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2024Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	708000	usd
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	74000	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83384000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82013000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84593000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77317000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1903000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4636000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26132000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34311000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50155000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53870000	usd
CY2024	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29401000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29532000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9544000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11545000	usd
CY2024	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7064000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7002000	usd
CY2024	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-435000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	807000	usd
CY2024	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	57511000	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	59126000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7276000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	807000	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5335000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13547604	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13547604	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13541559	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13541559	shares
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	85000	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	74000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5335000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4636000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1118000	usd
CY2024	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	253000	usd
CY2024	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	634000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1903000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7276000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5335000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	1118000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	864000	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1867000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2246000	usd
CY2024	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-435000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1066000	usd
CY2023	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	952000	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	807000	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	476000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	195000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1991000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1308000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	167000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	184000	usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	169000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	465000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2465000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-109000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-145000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1169000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-907000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-683000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1706000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6137000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3972000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	836000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2872000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-836000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2872000	usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	253000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	85000	usd
CY2024	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	634000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	74000	usd
CY2024	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	146000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-527000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7500000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1111000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10118000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9007000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2618000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10118000	usd
CY2024	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	usd
CY2023	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	368000	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	231000	usd
CY2024	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	4	subsidiary
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounts receivable realization, revenue recognition, valuation allowance for deferred tax assets, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions. We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources. Actual amounts could differ significantly from amounts previously estimated.</span></div>
CY2024Q2	us-gaap	Cash Cash	2600000	usd
CY2023Q2	us-gaap	Cash Cash	10100000	usd
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	csbr	Number Of Major Institutions With Cash Balances NumberOfMajorInstitutionsWithCashBalances	3	institution
CY2024Q2	csbr	Number Of Major Institutions With Cash Balances NumberOfMajorInstitutionsWithCashBalances	3	institution
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7300000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6100000	usd
CY2024Q2	csbr	Working Capital Deficit WorkingCapitalDeficit	7900000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84600000	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-32000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	usd
CY2023	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-95000	usd
CY2024Q2	csbr	Accounts Receivable Excluding Unbilled Receivables Current AccountsReceivableExcludingUnbilledReceivablesCurrent	4886000	usd
CY2023Q2	csbr	Accounts Receivable Excluding Unbilled Receivables Current AccountsReceivableExcludingUnbilledReceivablesCurrent	3843000	usd
CY2022Q2	csbr	Accounts Receivable Excluding Unbilled Receivables Current AccountsReceivableExcludingUnbilledReceivablesCurrent	6037000	usd
CY2024Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	5941000	usd
CY2023Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	4993000	usd
CY2022Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	4106000	usd
CY2024Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	10827000	usd
CY2023Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	8836000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	10143000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1301000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	825000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	630000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9526000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8011000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9513000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12094000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12776000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16112000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15816000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10391000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8630000	usd
CY2024Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	5721000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7186000	usd
CY2024Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	1900000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	2200000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1700000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2100000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1000000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1000000	usd
CY2023	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024Q2	us-gaap	Servicing Asset ServicingAsset	1900000	usd
CY2023Q2	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	807000	usd
CY2024	us-gaap	Hosting Arrangement Service Contract Implementation Cost Expense Amortization HostingArrangementServiceContractImplementationCostExpenseAmortization	0	usd
CY2023	us-gaap	Hosting Arrangement Service Contract Implementation Cost Expense Amortization HostingArrangementServiceContractImplementationCostExpenseAmortization	630000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	160000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	140000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	80000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	7000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	387000	usd
CY2024Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	16000	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	371000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50155000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53870000	usd
CY2024	us-gaap	Royalty Expense RoyaltyExpense	362000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	212000	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1100000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	864000	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1118000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	864000	usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.040
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.045
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.029
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.039
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.63
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.64
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.61
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.63
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.75
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.31
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1775667	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.80
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y7M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2683000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	444730	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.08
CY2024	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y6M
CY2024	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	0	usd
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	155449	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.31
CY2024	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	50535	shares
CY2024	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	4.82
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	40750	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.21
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	54166	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.78
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1919497	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.04
CY2024	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P5Y2M12D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2172000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1919497	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.04
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2172000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1484895	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.65
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2172000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1658239	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.51
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6131000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	186720	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.22
CY2023	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y4M24D
CY2023	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	0	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	36209	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.21
CY2023	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	13874	shares
CY2023	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	3.93
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14625	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.94
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4584	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.40
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1775667	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.80
CY2023	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P4Y7M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2683000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1775667	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.80
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y7M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2683000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1438807	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M18D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2681000	usd
CY2023Q1	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	5000000	usd
CY2024	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	120300	shares
CY2024	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	5.73
CY2024	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	708000	usd
CY2024Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	4300000	usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	usd
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-39000	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-32000	usd
CY2024	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2024	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	7000	usd
CY2024	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-39000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-32000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	15000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	53000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	68000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	15000	usd
CY2023	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	53000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.023
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2024	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.004
CY2023	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.005
CY2024	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	0
CY2023	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.185
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.238
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.013
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1269000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	273000	usd
CY2024Q2	csbr	Deferred Tax Assets Tax Deferred Expense Operating Leases DeferredTaxAssetsTaxDeferredExpenseOperatingLeases	279000	usd
CY2023Q2	csbr	Deferred Tax Assets Tax Deferred Expense Operating Leases DeferredTaxAssetsTaxDeferredExpenseOperatingLeases	403000	usd
CY2024Q2	csbr	Deferred Tax Liability Deferred Expense Depreciation And Amortization DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization	318000	usd
CY2023Q2	csbr	Deferred Tax Liability Deferred Expense Depreciation And Amortization DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization	297000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3792000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4024000	usd
CY2024Q2	csbr	Deferred Tax Liabilities Capitalized Research And Development Costs DeferredTaxLiabilitiesCapitalizedResearchAndDevelopmentCosts	4046000	usd
CY2023Q2	csbr	Deferred Tax Liabilities Capitalized Research And Development Costs DeferredTaxLiabilitiesCapitalizedResearchAndDevelopmentCosts	2597000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9038000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9756000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18106000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16756000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18106000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16756000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18100000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16800000	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1400000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1300000	usd
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	38600000	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	41300000	usd
CY2013Q2	csbr	Operating Loss Carryforwards Limitations On Use Amount OperatingLossCarryforwardsLimitationsOnUseAmount	12000000	usd
CY2024Q2	csbr	Operating Loss Carryforwards Limitations On Use Amount OperatingLossCarryforwardsLimitationsOnUseAmount	432000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7276000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5335000	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13547604	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13547604	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13541559	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13541559	shares
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1919497	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1775667	shares
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	1800000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1900000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6252000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7318000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1337000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1208000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6093000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7391000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0588
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0582
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2902000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2950000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2916000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2867000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2392000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14027000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6597000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	7430000	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	1680000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1566000	usd
CY2024	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	146000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	135000	usd
CY2024	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	15000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	19000	usd
CY2024	us-gaap	Lease Cost LeaseCost	1841000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1720000	usd

Files In Submission

Name	View Source	Status
csbr-20240430_def.xml	Edgar Link	unprocessable
csbr-20240430_cal.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
0001628280-24-032321-index-headers.html	Edgar Link	pending
0001628280-24-032321-index.html	Edgar Link	pending
0001628280-24-032321.txt	Edgar Link	pending
0001628280-24-032321-xbrl.zip	Edgar Link	pending
csbr-20240430.htm	Edgar Link	pending
csbr-20240430.xsd	Edgar Link	pending
csbrex214302024.htm	Edgar Link	pending
csbrex2314302024.htm	Edgar Link	pending
csbrex3114302024.htm	Edgar Link	pending
csbrex3124302024.htm	Edgar Link	pending
csbrex3214302024.htm	Edgar Link	pending
csbrex414302024.htm	Edgar Link	pending
csbrex974302024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
csbr-20240430_lab.xml	Edgar Link	unprocessable
csbr-20240430_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
csbr-20240430_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2024 Q3 Form 10-K Financial Statement

#000162828024032321 Filed on July 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2024 Q3 Form 10-K Financial Statement

#000162828024032321 Filed on July 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr